BMJ Open (Apr 2023)

Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I–II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)

  • Yoshiyuki Takahashi,
  • Hisashi Noma,
  • Akiko Saito,
  • Keizo Horibe,
  • Hirotoshi Sakaguchi,
  • Katsustugu Umeda,
  • Itaru Kato,
  • Kimiyoshi Sakaguchi,
  • Hidefumi Hiramatsu,
  • Hiroyuki Ishida,
  • Hiromasa Yabe,
  • Hiroaki Goto,
  • Yuta Kawahara,
  • Yuka Iijima Yamashita,
  • Masashi Sanada,
  • Takao Deguchi,
  • Takashi Taga,
  • Souichi Adachi

DOI
https://doi.org/10.1136/bmjopen-2022-070051
Journal volume & issue
Vol. 13, no. 4

Abstract

Read online

Introduction Relapsed and refractory B-cell acute lymphoblastic leukaemia (R/R-B-ALL) is linked to a significant relapse rate after allogeneic haematopoietic cell transplantation (allo-HCT) in children, adolescents and young adults (CAYA). No standard treatment has been established to prevent relapse after allo-HCT for R/R-B-ALL, which is an unmet medical need. The administration of blinatumomab after allo-HCT is expected to enhance the antileukaemic effect on residual CD19-positive blasts by donor-derived CD3-positive T-cells.Methods and analysis The goal of this multicentre, open-label, uncontrolled, phase I–II clinical trial is to assess the safety and effectiveness of post-transplant maintenance therapy with blinatumomab for CAYA patients (25 years old or younger) with CD19-positive R/R-B-ALL who have received allo-HCT beyond first complete remission (CR) and have CR with haematological recovery between 30 and 100 days after allo-HCT. Eighty-five paediatric institutions in Japan are participating in this study. Forty-one patients will enrol within 2.25-year enrolment period and follow-up period is 1 year. The primary endpoints are the treatment completion rate for phase I study and the 1-year graft-versus-host disease-free/relapse-free survival rate for phase II study, respectively.Ethics and dissemination This research was approved by the Central Review Board at National Hospital Organization Nagoya Medical Center (Nagoya, Japan) on 21 January 2022 and was registered at the Japan Registry of Clinical Trials (jRCT) on 3 March 2022. Written informed consent is obtained from all patients and/or their guardians. The results of this study will be disseminated through peer-reviewed publications and conference presentations.Trial registration number jRCTs041210154.